Aarti Pharmalabs Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.8 pts less than Nifty Microcap 250 and 5.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aarti Pharmalabs reported FY2026 standalone revenue of Rs 1,79,755 lakhs, up marginally by 1.5% from Rs 1,77,135 lakhs in FY2025. However, standalone net profit declined sharply to Rs 17,620 lakhs from Rs 25,735 lakhs in the prior year, a drop of about 31.5%. The profit decline was driven by near-doubling of finance costs (Rs 4,690 lakhs vs Rs 2,563 lakhs), foreign exchange loss of Rs 3,321 lakhs versus a gain of Rs 169 lakhs previously, and higher depreciation. The company also took an exceptional charge of Rs 279 lakhs for new labour code provisions. The Q3 FY26 figures were restated due to an omitted forward contract fair value adjustment identified during annual accounts preparation. The company declared a final dividend of Rs 2 per share (40%). The auditor issued an unmodified opinion.
The sharp profit decline despite flat revenue growth signals cost pressures and margin compression, which could weigh on the stock price. The restatement and labour code provision are minor concerns but the clean audit opinion is positive.